Acoltremon is under clinical development by Alcon and currently in Phase III for Keratoconjunctivitis Sicca (Dry Eye). According to GlobalData, Phase III drugs for Keratoconjunctivitis Sicca (Dry Eye) have a 26% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Acoltremon’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Acoltremon overview
Acoltremon (AR-15512) is under development for the treatment of dry eye syndrome. It is administered through ophthalmic route as a solution. It acts by targeting TRPM8 receptor.
It was also under development for vaginal dryness.
Alcon overview
Alcon is engaged in the development and manufacturing of devices in the field of ophthalmology. The company’s portfolio encompasses contact lenses and surgical products, including implantables, consumables and surgical equipment. The company’s products are indicated for the treatment of various conditions such as cataracts, glaucoma, retinal diseases and refractive errors. It conducts clinical trials to evaluate the safety and efficacy of its products for the prevention and cure of blindness and different eye diseases. Alcon’s pipeline products are developed through collaboration with institutions, medical innovators, research advisors and academic thought leaders. The company has operations in the Americas, Europe, the Middle East, and Africa and Asia Pacific. Alcon is headquartered in Fribourg, Switzerland.
For a complete picture of Acoltremon’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.